World Health Organization approved SK bioscience as supplier of Novavax Nuvaxovid COVID-19 vaccine
On Sept. 2, 2022, Novavax announced that the World Health Organization (WHO) had approved a variation to allow…
-
-
Novavax Nuvaxovid COVID-19 vaccine recommended by CHMP for expanded conditional Marketing Authorization in EU as booster for adults
On Sept. 1, 2022, Novavax announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional marketing…
-
$838 Million neurosciences center broke ground in Connecticut
On Aug. 31, 2022, the Yale New Haven Hospital broke ground on the $838 million, 505,000 square foot…
-
Novavax Nuvaxovid COVID-19 vaccine granted expanded conditional marketing authorization in UK for use in adolescents aged 12 through 17
On Aug. 26, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
-
Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5 adapted bivalent vaccine
On Aug. 26, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
-
Pfizer and BioNTech announced updated COVID-19 vaccine data supporting efficacy in children 6 months through 4 years of age
On Aug. 23, 2022, Pfizer and BioNTech announced updated efficacy results from a Phase 2/3 trial evaluating a…
-
Moderna completed application to U.S. FDA for EUA of omicron-targeting bivalent Covid-19 booster vaccine
On Aug. 22, 2022, the Food and Drug Administration (FDA) amended the emergency use authorization (EUA) of Moderna…
-
Moderna announced supplying 12 million doses of Omicron-containing bivalent COVID-19 booster vaccines to Government of Canada
On Aug. 23, 2022, Moderna announced that the Government of Canada had exercised its option to purchase an…
-
Pfizer and BioNTech submitted application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine
On Aug. 22, 2022, Pfizer and BioNTech announced they had completed a submission to the U.S. Food and…
-
U.S. FDA granted EUA for Novavax COVID-19 vaccine, adjuvanted for adolescents Aged 12 through 17
On Aug. 19, 2022, Novavax announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) had received expanded emergency use…
-
Novavax Nuvaxovid COVID-19 vaccine granted expanded provisional approval in New Zealand for adolescents aged 12 through 17
On Aug. 18, 2022, Novavax announced that New Zealand’s Medsafe had granted expanded provisional approval for Nuvaxovid (NVX-CoV2373)…
-
Medicines and Healthcare Products Regulatory Agency authorized Moderna’s Omicron-containing bivalent booster in the UK
On Aug. 15, 2022, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK…
-
Novavax Nuvaxovid COVID-19 vaccine approved in South Korea for use in adolescents aged 12 through 17
On Aug. 12, 2022, Novavax announced that partner, SK bioscience, had received a Post Approval Change Application approval…
-
Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody response
On Aug. 9, 2022, Moderna announced an amendment to its agreement with the European Commission (EC) to convert…
-
Novavax announced initiation of phase 2b/3 Hummingbird global clinical trial for COVID-19 vaccine in children aged six months through 11 years
On Aug. 4, 2022, Novavax announced the initiation of its Phase 2b/3 Hummingbird global clinical trial. The trial…
-
Biotechnology | COVID-19 | NIH | Therapeutics | Vaccine
HHS announced 66 million doses of Moderna’s variant-specific COVID-19 vaccine booster for potential use in Fall and Winter 2022
On Jul. 29, 2022, the U.S. Department of Health and Human Services (HHS), in collaboration with the U.S….
-
Pfizer and BioNTech announced clinical trial of next-generation vaccine candidate based on enhanced spike protein design
On Jul. 27, 2022, Pfizer and BioNTech announced that the companies had initiated a randomized, active-controlled, observer-blind, Phase…
-
Novavax announced expanded approval of Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 in Japan
On Jul. 26, 2022, Novavax announced that Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval from…
-
Novavax Nuvaxovid COVID-19 vaccine granted provisional registration in Australia for use in adolescents aged 12 through 17
On Jul. 26, 2022, Novavax announced that the Australian Therapeutic Goods Agency had granted expanded approval for provisional…
-
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 Vacations Redux
COVID-19 Vacations Redux iIlustrates once again the pits and perils vacation travelers face as they begin their Summer…
-
EMA Committee for Medicinal Products for Human Use recommended use of the Moderna COVID-19 booster in adolescents (12-17 years)
On Jul. 23, 2022, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended…
-
CHMP adopted positive opinion recommending Veklury (Remdesivir) receive full Marketing Authorization for teatment of patients with COVID-19
On Jul. 22, 2022, Gilead Sciences announced that the Committee for Medicinal Products for Human Use (CHMP) of…
-
Novavax announced expanded agreement with SK bioscience to manufacture COVID-19 vaccine with Omicron variant
On Jul. 19, 2022, Novavax announced that it had signed agreements with its partner, SK bioscience, for the…
-
Australia TGA granted provisional approval for Moderna’s COVID-19 vaccine in children aged six months to five years
On Jul. 19, 2022, Moderna said that Australia’s drug regulator Therapeutic Goods Administration (TGA) has provisionally approved its…
-
U.S. CDC endorsed Advisory Committee on Immunization Practices’ recommendation for Novavax COVID-19 vaccine
On Jul. 19, 2022, Novavax announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee…
-
Gilead Sciences signed joint procurement agreement with the European Commission for Veklury (Remdesivir)
On Jul. 19, 2022, Gilead Sciences and the European Commission announced a new joint procurement agreement (JPA) that…
-
COVID-19 | Infectious Disease | NIH | Therapeutics | Vaccine
Vaccine-induced immune response to Omicron wanes substantially over time
On Jul. 19, 2022, the National Institutes of Health (NIH) announced that although COVID-19 booster vaccinations in adults…
-
Health Canada authorized Moderna’s COVID-19 vaccine in young children (6 months-5 years)
On Jul. 14, 2022, Health Canada announced it had authorized the use of the Moderna Spikevax COVID-19 vaccine…
-
U.S. FDA granted EUA for Novavax COVID-19 vaccine, adjuvanted for individuals aged 18 and over
On Jul. 13, 2022, Novavax announced that its COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) had received emergency use authorization from…
-
NIH launched clinical trial of mRNA Nipah virus vaccine
On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…
